INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 201 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 1.09 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $12,095,000 | +86.7% | 97,600 | 0.0% | 0.24% | +37.9% |
| Q3 2019 | $6,477,000 | -16.6% | 97,600 | 0.0% | 0.17% | -2.2% |
| Q2 2019 | $7,766,000 | +992.3% | 97,600 | +1634.5% | 0.18% | +836.8% |
| Q3 2018 | $711,000 | -93.5% | 5,627 | -99.2% | 0.02% | -91.0% |
| Q3 2017 | $11,014,000 | +132.7% | 680,000 | +3300.0% | 0.21% | -54.7% |
| Q2 2014 | $4,733,000 | – | 20,000 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |